Humacyte Stock Market Value
| HUMA Stock | USD 4.51 0.14 3.01% |
| Symbol | Humacyte |
Humacyte Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Humacyte 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Humacyte's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Humacyte.
| 11/25/2024 |
| 12/25/2024 |
If you would invest 0.00 in Humacyte on November 25, 2024 and sell it all today you would earn a total of 0.00 from holding Humacyte or generate 0.0% return on investment in Humacyte over 30 days. Humacyte is related to or competes with Crinetics Pharmaceuticals, Viridian Therapeutics, Cytokinetics, Structure Therapeutics, Immunocore Holdings, Mirum Pharmaceuticals, and Larimar Therapeutics. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues... More
Humacyte Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Humacyte's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Humacyte upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 33.89 | |||
| Value At Risk | (10.78) | |||
| Potential Upside | 7.57 |
Humacyte Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Humacyte's standard deviation. In reality, there are many statistical measures that can use Humacyte historical prices to predict the future Humacyte's volatility.| Risk Adjusted Performance | 0.0082 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.01) |
Humacyte Backtested Returns
Humacyte holds Efficiency (Sharpe) Ratio of -0.0165, which attests that the entity had a -0.0165% return per unit of risk over the last 3 months. Humacyte exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Humacyte's Standard Deviation of 6.85, market risk adjusted performance of 0.0041, and Risk Adjusted Performance of 0.0082 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.69, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. At this point, Humacyte has a negative expected return of -0.11%. Please make sure to check out Humacyte's skewness, and the relationship between the treynor ratio and daily balance of power , to decide if Humacyte performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.05 |
Virtually no predictability
Humacyte has virtually no predictability. Overlapping area represents the amount of predictability between Humacyte time series from 25th of November 2024 to 10th of December 2024 and 10th of December 2024 to 25th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Humacyte price movement. The serial correlation of 0.05 indicates that only as little as 5.0% of current Humacyte price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.05 | |
| Spearman Rank Test | 0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Humacyte lagged returns against current returns
Autocorrelation, which is Humacyte stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Humacyte's stock expected returns. We can calculate the autocorrelation of Humacyte returns to help us make a trade decision. For example, suppose you find that Humacyte has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Humacyte regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Humacyte stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Humacyte stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Humacyte stock over time.
Current vs Lagged Prices |
| Timeline |
Humacyte Lagged Returns
When evaluating Humacyte's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Humacyte stock have on its future price. Humacyte autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Humacyte autocorrelation shows the relationship between Humacyte stock current value and its past values and can show if there is a momentum factor associated with investing in Humacyte.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out Humacyte Correlation, Humacyte Volatility and Humacyte Alpha and Beta module to complement your research on Humacyte. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Humacyte technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.